http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Euisun Jeong ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
S-590 Comparison of biologic characteristics between primary and metastatic sites in breast cancer
( Yu Kyung Chung ),( Euisun Jeong ),( Eun Mi Nam ),( Sun Hee Sung ),( Byung In Moon ),( Kyoung Eun Lee ) 대한내과학회 2016 대한내과학회 추계학술발표논문집 Vol.2016 No.1
Background: Adjuvant therapy after surgery in breast cancer is based upon to the biologic characteristics of primary lesion. As we can see in the cell line data, the expression of estrogen receptor was significantly decreased in endocrine resistance cell lines. So the biologic characteristics of metastatic lesion after adjuvant therapy could be different with that of primary lesion. In the literature, the rate of discordance in progesterone receptor (PR) is about 30% and most of the patients have lost the biologic expression with metastasis or relapse. In this study, we tried to elucidate the change of biologic characteristics of breast cancer patients after relapse or metastasis. Methods: We reviewed medical record of relapsed/metastatic breast cancer patients who have diagnosed between 2003 and 2013. We enrolled 58 patients who have paired biopsy samples of primary site and metastatic sites and evaluated the clinical and biologic characteristics including site of relapse, site of biopsy, estrogen receptor(ER), PR, HER2 expression by immunohistochemistry or FISH and survival, retrospectively. Results: The median age of these patients is 48 years old (29~76) and the median time to re-biopsy from primary site tissue confirm was 27.5 months (0 ~265). The most common metastatic biopsied site is the chest wall and the second, third is lung and liver. The loss of ER, PR expression with metastasis was showed in 15.5 % and 13.8%, respectively. The gain of ER, PR, HER2 expression was showed in 3.4 %, 3.4 %, 5.2 %, respectively. Conclusions: Our study showed the discordance rate of 19.0 %, 17.2 %, 5.2 % in ER, PR, HER2 expression, respectively. So re-biopsy can guide the therapeutic options which might be differ to that of original breast cancer in relapsed/metastatic breast cancer.
-
Discovery of an Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist
Kim, Seon-Mi,Lee, Minhee,Lee, So Young,Park, Euisun,Lee, Soo-Min,Kim, Eun Jeong,Han, Min Young,Yoo, Taekyung,Ann, Jihyae,Yoon, Suyoung,Lee, Jiyoun,Lee, Jeewoo American Chemical Society 2016 Journal of medicinal chemistry Vol.59 No.19
<P>We developed a compound library for orally available gonadotropin-releasing hormone (GnRH) receptor antagonists that were based on a uracil scaffold. On the basis of in vitro activity and CYP inhibition profile, we selected 18a (SKI2496) for further in vivo studies. Compound 18a exhibited more selective antagonistic activity toward the human GnRH receptors over the GnRHRs in monkeys and rats, and this compound also showed inhibitory effects on GnRH-mediated signaling pathways. Pharmacokinetic and pharmacodynamic evaluations of 18a revealed improved bioavailability and superior gonadotropic suppression activity compared with Elagolix, the most clinically advanced compound. Considering that 18a exhibited highly potent and selective antagonistic activity toward the hGnRHRs along with favorable pharmacokinetic profiles, we believe that 18a may represent a promising candidate for an orally available hormonal therapy.</P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
